We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

114 hedge funds and large institutions have $104M invested in Akebia Therapeutics in 2024 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

208% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 13

46% more call options, than puts

Call options by funds: $2.88M | Put options by funds: $1.97M

42% more capital invested

Capital invested by funds: $73.5M → $104M (+$30.8M)

31% more funds holding

Funds holding: 87 → 114 (+27)

4% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.18% less ownership

Funds ownership: 29.42% → 27.24% (-2.2%)

Holders
114
Holders Change
+27
Holders Change %
+31.03%
% of All Funds
1.64%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
40
Increased
26
Reduced
25
Closed
13
Calls
$2.88M
Puts
$1.97M
Net Calls
+$905K
Net Calls Change
+$70K

Top Buyers

Rank Fund Capital Flow
1
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$3.21M
2
Goldman Sachs
Goldman Sachs
New York
+$2.15M
3
Marshall Wace
Marshall Wace
United Kingdom
+$1.64M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$1.26M
5
Millennium Management
Millennium Management
New York
+$1.06M

Top Sellers

Rank Fund Capital Flow
1
AIM
Alerce Investment Management
Illinois
-$4.8M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$2.57M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.8M
4
BlackRock
BlackRock
New York
-$933K
5
Morgan Stanley
Morgan Stanley
New York
-$894K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$384K +$336K +210,000 New
SC
27
Sapient Capital
Indiana
$366K – – –
Citigroup
28
Citigroup
New York
$344K -$188K -117,781 -39%
PAS
29
Point72 Asia (Singapore)
Singapore
$341K +$298K +186,232 New
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
$327K +$286K +178,793 New
Russell Investments Group
31
Russell Investments Group
United Kingdom
$322K -$10K -6,259 -3%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$293K -$11.2K -7,000 -4%
Tudor Investment Corp
33
Tudor Investment Corp
Connecticut
$260K – – –
YIH
34
Y-Intercept (HK)
Hong Kong
$258K +$225K +140,925 New
ECM
35
ExodusPoint Capital Management
New York
$252K -$168K -105,232 -43%
Creative Planning
36
Creative Planning
Kansas
$203K – – –
OCM
37
Orchard Capital Management
Illinois
$198K +$34.6K +21,634 +25%
UBS Group
38
UBS Group
Switzerland
$182K -$92.2K -57,692 -37%
DZ Bank
39
DZ Bank
Germany
$169K +$148K +92,554 New
Citadel Advisors
40
Citadel Advisors
Florida
$152K -$168K -105,360 -56%
BHCM
41
Brevan Howard Capital Management
Jersey
$149K +$131K +81,676 New
Charles Schwab
42
Charles Schwab
California
$146K – – –
OAC
43
OMERS Administration Corp
Ontario, Canada
$141K +$123K +77,000 New
HighTower Advisors
44
HighTower Advisors
Illinois
$135K -$36.8K -23,000 -24%
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$126K +$109K +68,475 New
T. Rowe Price Associates
46
T. Rowe Price Associates
Maryland
$110K – – –
CAS
47
CTC Alternative Strategies
Illinois
$107K +$93.8K +58,700 New
EDRH
48
Edmond de Rothschild Holding
Switzerland
$91.5K – – –
CAMG
49
CWA Asset Management Group
Florida
$89.7K – – –
DM
50
Deerfield Management
New York
$86.2K +$75.3K +47,100 New
1
2
3 4 5

AKBA Hedge Fund Activity: Q1 2024 in Review

114 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2024, worth a combined $104M — up 42% from $73.5M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new AKBA positions and 13 closed out — a net gain of 27 holders — while 26 added to existing stakes and 25 trimmed.

The largest buyer was Qube Research & Technologies (QRT), adding an estimated $3.21M. The largest seller was Alerce Investment Management, cutting an estimated $4.8M.

  • 114 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2024, up from 87 in Q4 2023.
  • Funds reported $104M of Akebia Therapeutics stock for Q1 2024, up 42% quarter-over-quarter.
  • 40 funds opened new Akebia Therapeutics positions in Q1 2024 and 13 closed out, a net change of +27 holders.
  • The largest Akebia Therapeutics buyer in Q1 2024 was Qube Research & Technologies (QRT), an estimated $3.21M added.
  • The largest Akebia Therapeutics seller in Q1 2024 was Alerce Investment Management, an estimated $4.8M sold.

Based on aggregated 13F filings for Q1 2024.